GLP-1 weight regain after stopping: what the Oxford data actually shows

What did @danielle.thompson6421 actually say?

Here's the problem: the transcript provided has nothing to do with GLP-1s, Oxford studies, or weight regain. The actual words spoken are abstract, poetic fragments — "Time melts like ice, where do you go" and "let the silence every wash their shine slow" — with no factual health content whatsoever. So we're fact-checking the caption, not the video.

The caption claims an Oxford study tracked over 9,000 people who stopped medications like Ozempic and found weight regain happened at roughly 0.4 kg per month. That's a specific, checkable claim. The creator also mentions the regain was "faster than expected," which is a characterisation worth examining. But because the spoken content is entirely unrelated to these claims, it's worth flagging upfront: viewers are reading claims in a caption that the video itself never actually supports or explains.

Does the science back this up?

The core statistic — roughly 0.4 kg per month regain after stopping semaglutide — is in the right ballpark based on what the published literature shows. But the Oxford attribution needs scrutiny, and "faster than expected" is doing a lot of unearned work.

The most cited trial on this topic is the STEP 1 extension study (Wilding et al., 2022, Diabetes, Obesity and Metabolism), which tracked participants one year after stopping semaglutide 2.4 mg. By week 120, participants had regained about two-thirds of their lost weight. That works out to roughly 0.3 to 0.5 kg per month depending on the individual's starting point, so the 0.4 kg figure is plausible. A separate analysis published in the BMJ (2024) using UK primary care data — which is more likely the "Oxford-linked" research being referenced — found similar patterns in a real-world cohort. Sample sizes in the thousands were used. So the numbers aren't invented. They're just being presented without context about what "faster than expected" actually means compared to other anti-obesity interventions.

What did they get wrong (or right)?

Credit where it's due: the 0.4 kg per month figure aligns reasonably with published data, and drawing attention to post-discontinuation regain is genuinely useful public health communication. Most GLP-1 marketing glosses over this entirely.

But there are real problems here. First, the caption lists "Ozempic and Ozempic" as two separate medications, which suggests either a typo for Wegovy or a basic misunderstanding of the product landscape. Ozempic and Wegovy are both semaglutide, but they are approved for different indications at different doses. Conflating them, or failing to distinguish them, matters clinically. Second, "faster than expected" implies there was a prior expectation being measured against. There wasn't a single agreed benchmark. Regain rates after stopping other anti-obesity treatments like orlistat or older agents are also significant, so framing this as uniquely alarming about GLP-1s without that comparison is misleading. Third, and most importantly, the transcript has zero overlap with these claims. Whatever the video's audio actually contains, it is not this information.

What should you actually know?

Weight regain after stopping GLP-1 receptor agonists is real, well-documented, and not a scandal, it's a predictable pharmacological outcome. These drugs work while you take them. When you stop, the appetite-suppressing and metabolic effects stop too. The STEP 1 extension data (Wilding et al., 2022) showed participants regained approximately 11.6 kg over 52 weeks after stopping semaglutide, having lost around 17.3 kg during treatment. That's meaningful but not mysterious.

What this means practically is that GLP-1 therapy is increasingly being understood as a long-term or indefinite treatment for many people, not a short course. Stopping without a plan for maintaining lifestyle changes tends to result in significant regain. Some patients do maintain meaningful weight loss after stopping, particularly those who used the treatment window to build sustainable habits, but they are not the majority in trial data.

• Regain does not mean the medication failed. It means the underlying condition, obesity, is chronic.
• Discontinuation rates in real-world data are high, often over 50% at one year, making this a pressing clinical issue.
• Anyone considering stopping should discuss a transition plan with a prescribing clinician, not make that call based on a TikTok caption.